Treating Refractory Hematological Malignancies – Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A:Life Sciences Market Research Reports

Life Sciences Market Research Reports

Curious about BaaS? Get the full feature comparison in our free eBook comparing the time to create your own cloud backend to a Backend as a Service like Kinvey. From our sponsors

Treating Refractory Hematological Malignancies – Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A Sep 19th 2013, 00:00, by swapnil The report provides an overview of the therapies for Multiple Myeloma (Newly diagnosed – NDMM and relapsed/ refractory – RRMM), unmet need, and limitations of the current standard of care (SoC) for relapsed and refractory MM pts.  The report highlights the competition and commercial opportunity in pursuing this therapy area – Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them. Detailed financial and competitive analysis of the companies leading in this field for this indication – Celgene, Amgen (post-acquisition of Onyx pharma), and MorphoSys are available within this full report.  … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=115853. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/treating-refractory-hematological-malignancies-multiple-myeloma-mm-new-treatment-options-driving-in-licensing-and-ma-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions